Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.

[1]  S. Hah.  Recent advances in biomedical applications of accelerator mass spectrometry , 2009, Journal of Biomedical Science.

[2]  S. Hah.  Determination of Protein-Ligand Interactions Using Accelerator Mass Spectrometry: Modified Crosslinking Assay , 2009, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[3]  Sang Soo Hah,et al.  Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. , 2007, Chemical research in toxicology.

[4]  V. Schramm,et al.  Incorporation of extracellular 8-oxodG into DNA and RNA requires purine nucleoside phosphorylase in MCF-7 cells , 2007, Nucleic acids research.

[5]  J. Gregg,et al.  A sample preparation protocol for quantification of radiolabeled nucleoside incorporation into DNA by accelerator mass spectrometry , 2007 .

[6]  M. Saunders,et al.  Management of advanced colorectal cancer: state of the art , 2006, British Journal of Cancer.

[7]  S. Hah,et al.  Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. , 2005, Chemical research in toxicology.

[8]  H. M. Kim,et al.  Hydantoin derivative formation from oxidation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG) and incorporation of 14C-labeled 8-oxodG into the DNA of human breast cancer cells. , 2005, Bioorganic & medicinal chemistry letters.

[9]  J. Vogel.  Accelerator mass spectrometry for quantitative in vivo tracing. , 2005, BioTechniques.

[10]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[11]  M. Fuertes,et al.  Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. , 2003, Chemical reviews.

[12]  R. Riccardi,et al.  Cellular and molecular aspects of drugs of the future: oxaliplatin , 2002, Cellular and Molecular Life Sciences CMLS.

[13]  B. Desoize,et al.  Particular aspects of platinum compounds used at present in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[14]  J. Essigmann,et al.  Recognition of cisplatin adducts by cellular proteins. , 2001, Mutation research.

[15]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[16]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[17]  P B Laub,et al.  Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.

[18]  R. Ozols,et al.  Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. , 1994, Cancer research.

[19]  A. Eastman.  Separation and characterization of products resulting from the reaction of cis-diamminedichloroplatinum (II) with deoxyribonucleosides. , 1982, Biochemistry.

[20]  S. Chaney,et al.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. , 2005, Critical reviews in oncology/hematology.

[21]  R. C. Garner,et al.  Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry , 2004, Analytical and bioanalytical chemistry.

[22]  J. Yachnin,et al.  Pharmacokinetics of oxaliplatin in humans , 2002, Medical oncology.

[23]  A. Eastman,et al.  Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.